Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Ecaterina Berzan  (Berzan 1) 1 Article
Diabetes
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Endocrinol Metab. 2021;36(2):256-269.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.987
  • 5,244 View
  • 297 Download
  • 8 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Citations

Citations to this article as recorded by  
  • Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
    Ayodele Odutayo, Adeera Levin
    Clinical Journal of the American Society of Nephrology.2023; 18(5): 557.     CrossRef
  • Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
    Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
    Endocrinology and Metabolism.2023; 38(1): 43.     CrossRef
  • Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
    Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
    Endocrinology and Metabolism.2023; 38(4): 359.     CrossRef
  • SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
    A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
    Biomedicine & Pharmacotherapy.2023; 168: 115755.     CrossRef
  • Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
    Emma S. Speedtsberg, Martin Tepel
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Management of CKD
    Nimrit Goraya, Jennifer D. Moran
    Nephrology Self-Assessment Program.2022; 21(2): 146.     CrossRef
  • Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
    Peter Kolkhof, Amer Joseph, Ulrich Kintscher
    Pharmacological Research.2021; 172: 105859.     CrossRef
  • Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
    Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
    Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
    touchREVIEWS in Endocrinology.2021; 17(2): 84.     CrossRef
  • Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
    Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
    Frontiers in Medicine.2021;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism